N

    Nuvation Bio Inc (NUVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $6.67
    +0.01 (+0.08%)

    Market Cap: $2.34B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(16/23)
    Avg Surprise
    -149.60%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.11-22.2%
    60d ago$-0.11-22.2%
    30d ago$-0.11-22.2%
    7d ago$-0.11-22.2%
    Current$-0.09
    Revenue Consensus
    $36M
    Range$28M - $40M
    12 analysts
    Dec 31, 2026
    EPS Consensus$-0.13
    Range$-0.13 - $-0.13
    2 analysts
    Revenue Consensus
    $74M
    Range$51M - $95M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.13---
    Sep 26EST
    		-$-0.09---
    Jun 26
    		$-0.15$-0.15+0.00%Beat+11.8%
    Mar 26
    		$0.01N/A+123.15%Beat+107.7%
    Dec 25
    		$-0.11$-0.09-22.22%Miss+5.6%
    Sep 25
    		$-0.16$-0.17+5.88%Beat-33.3%
    Jun 25
    		$-0.17$-0.17+0.00%Beat+90.8%
    Mar 25
    		$-0.13$-0.12-8.33%Miss-225.0%
    Dec 24
    		$-0.12$-0.12+2.92%Beat-94.2%
    Sep 24
    		$-0.12$-0.10-20.00%Miss-100.0%
    Jun 24
    		$-1.85$-0.05-3600.00%Miss-2542.9%
    Mar 24
    		$-0.04$-0.05+20.00%Beat+50.0%
    Dec 23
    		$-0.06$-0.10+40.00%Beat+40.0%
    Sep 23
    		$-0.06$-0.08+25.00%Beat+45.5%
    Jun 23
    		$-0.07$-0.08+12.50%Beat+50.0%
    Mar 23
    		$-0.08$-0.06-33.33%Miss+0.0%
    Dec 22
    		$-0.10$-0.11+9.09%Beat+16.7%
    Sep 22
    		$-0.11$-0.15+26.67%Beat-22.2%
    Jun 22
    		$-0.14$-0.11-27.27%Miss-75.0%
    Mar 22
    		$-0.08$-0.13+38.46%Beat+27.3%
    Dec 21
    		$-0.12$-0.12+0.00%Beat-200.0%
    Sep 21
    		$-0.09$-0.10+10.00%Beat-125.0%
    Jun 21
    		$-0.08$-0.10+20.00%Beat-
    Mar 21
    		$-0.11$-0.06-83.33%Miss-
    Dec 20
    		$-0.04$-0.05+20.00%Beat-
    Sep 20
    		$-0.04N/AN/ABeat-
    Jun 20
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-16.26EV/EBITDA2.23x
    Price/FCF-18.03xFCF Yield-5.55%
    Profitability
    Profit Margin-88.20%Operating Margin-161.10%
    ROE-47.80%ROIC-21.19%
    Financial Health
    Debt/Equity0.98xInterest Coverage-3.73x
    Current Ratio8.37xQuick Ratio8.14x
    Trading Statistics
    Beta1.52Avg Volume5.52M
    52-Week High$9.7552-Week Low$2.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.91
    SMA 20$6.64
    SMA 50$6.29
    SMA 200$5.92
    EMA 10$6.79
    EMA 20$6.67
    EMA 50$6.27
    EMA 200$5.41

    MACD

    Line: 0.18Signal: 0.20Hist: -0.03

    ADX

    ADX: 16.0+DI: 22.5-DI: 23.3

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down56.0
    PSAR$6.37

    Bollinger Bands

    Upper Band$7.30
    Lower Band$5.98
    %B Position1988%(Upper)
    Band Width0.52

    RSI (14-Day)

    Neutral
    51.7

    Momentum Oscillators

    Stoch %K52.5
    Stoch %D59.2
    Williams %R-53.8
    ROC (10d)2.9%
    Momentum0.18
    CCI (20d)-2.5
    MFI (14d)42.0

    Volatility Measures

    ATR (14d)$0.37(5.5%)
    StdDev (20d)0.33
    Hist Vol65.7%(High)

    Volume Flow

    VWAP$6.64
    OBV116.6M
    AD Line89.6M
    CMF (20d)0.006

    Volume Metrics

    Avg Vol (20d)5.5M
    Vol Ratio0.6x
    VWMA (20d)$6.63

    Pivot Points

    R3$7.27
    R2$7.13
    R1$6.90
    Pivot Point$6.76
    S1$6.52
    S2$6.39
    S3$6.15

    Advanced Oscillators

    TSI12.19
    Ultimate Osc46.6
    KST106.35

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$31.69M$83.23M$41.87M$13.12M$4.83M$3.08M$-2,162,000$727,000$1.44M$0$264,000$0
    Cost of Revenue$0$0$-8,019,000$3.35M$0$0$-2,862,000$1.51M$1.35M$0$55,000$0
    Gross Profit$31.69M$83.23M$49.88M$9.77M$4.83M$3.08M$700,000$-788,000$88,000$0$209,000$0
    Operating Expenses$82.72M$79.35M$83.92M$66.20M$68.42M$62.09M$62.52M$47.31M$470.47M$20.20M$20.83M$26.34M
    R&D$30.66M$35.05M$34.30M$28.85M$27.36M$24.60M$29.30M$27.73M$454.32M$12.84M$15.35M$18.56M
    SG&A$43.50M$38.68M$41.18M$37.36M$38.66M$35.39M$26.14M$19.58M$16.16M$7.36M$5.48M$7.78M
    Operating Income$-51,036,000$3.88M$-34,037,000$-56,434,000$-63,589,000$-59,004,000$-53,942,000$-48,101,000$-470,385,000$-20,199,000$-20,831,000$-26,339,000
    Interest Income$4.60M$5.11M$5.30M$6.03M$4.78M$5.32M$6.06M$6.73M$7.14M$7.13M$6.93M$6.52M
    Interest Expense$16.23M$6.71M$6.67M$6.53M$421,000$54,000$89,000$120,000$132,000$0$0$0
    Income Before Tax$-62,840,000$5.40M$-36,592,000$-55,792,000$-59,007,000$-53,236,000$-49,445,000$-41,210,000$-462,492,000$-14,792,000$-13,787,000$-19,649,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-62,840,000$5.40M$-36,592,000$-55,792,000$-59,007,000$-53,236,000$-49,445,000$-41,210,000$-462,492,000$-14,792,000$-13,787,000$-19,649,000
    EBITDA$-51,039,000$7.01M$-35,535,000$-55,727,000$-64,326,000$-59,670,000$-56,858,000$-49,745,000$-471,677,000$-24,685,000$-24,058,000$-29,559,000
    EBIT$-51,214,000$6.99M$-35,213,000$-55,291,000$-63,365,000$-58,506,000$-55,423,000$-47,805,000$-469,497,000$-21,923,000$-20,854,000$-26,184,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NUVB

    News

    Nuvation Bio (NUVB) CSO sells 100K shares at $7.09

    Nuvation Bio Inc.'s Chief Scientific Officer, Gary Hattersley, exercised options for 100,000 shares of Class A Common Stock at $1.87 per share and subsequently sold all 100,000 shares at a weighted-average price of $7.0924. This transaction, executed on August 19, 2026, was part of a Rule 10b5-1 trading plan established on December 4, 2025. After the exercise and sale, Hattersley directly holds 400,000 stock options, with the exercised option vesting schedule detailed for future equity.

    Stock Titan•8/21/26•
    Somewhat-Bearish

    Nuvation Bio (NYSE: NUVB) posts $31.7M Q2 revenue and $62.8M loss

    Nuvation Bio (NYSE: NUVB) announced Q2 2026 revenue of $31.7 million, driven by strong sales of its ROS1 inhibitor IBTROZI and collaboration agreements, representing a significant increase from the previous year. Despite the revenue growth, the company reported a net loss of $62.8 million due to high research and development and administrative expenses. Nuvation Bio also provided updates on its clinical pipeline, including positive Phase 2 data for safusidenib and strategic financial moves to strengthen its balance sheet.

    Stock Titan•8/6/26•
    Neutral

    4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

    Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

    Zacks Commentary•8/3/26•
    Neutral

    Nuvation Bio Inc. ( NUVB ) Expected to Beat Earnings Estimates: Should You Buy?

    Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Zacks Commentary•7/30/26•
    Somewhat-Bullish

    Nuvation Bio (NUVB) Corporate presentation Summary

    Nuvation Bio (NUVB) presented a corporate summary highlighting its focus on oncology medicines and strong financial position. The company emphasized the success of IBTROZI (taletrectinib), approved for advanced ROS1+ NSCLC, noting its high efficacy, favorable safety profile, and significant market potential. The presentation also touched upon a robust pipeline and accelerating adoption of first-line oncology drugs.

    Quartr•7/20/26•
    Bullish

    Frequently Asked Questions About NUVB

    Does NUVB pay dividends?
    Nuvation Bio Inc (NUVB) does not currently pay a regular dividend.
    What is NUVB's market cap?
    Nuvation Bio Inc (NUVB) has a market capitalization of $2.34B with a current stock price of $6.67.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In